Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Investing

Novo Nordisk CEO to step down as obesity drug competition intensifies

admin by admin
May 16, 2025
in Investing
0
Novo Nordisk CEO to step down as obesity drug competition intensifies
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Novo Nordisk said on Friday that Chief Executive Officer Lars Fruergaard Jørgensen will step down, a decision made jointly with the board as the company confronts mounting competitive and financial pressures.

The changes are being made “in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024,” the company said.

The Danish drugmaker said Jørgensen would remain in place “for a period” to help ensure a smooth leadership transition.

A formal search for his successor is underway, with an announcement expected in due course.

Jørgensen’s departure comes at a time when the company’s performance has been under scrutiny.

Shares in the pharmaceutical firm fell by more than 4% following the announcement in Copenhagen, while its US-listed stock dropped 5.61% in premarket trading.

The company’s shares have lost more than 24% of their value so far this year in the US, and close to 35% in Copenhagen.

Meanwhile, Eli Lilly has lost only about 5.8% YTD. Its share price was up by 1.36% in pre-market trading.

In a statement, Novo Nordisk said the decision was the result of internal discussions initiated by the Novo Nordisk Foundation, which considered the merits of accelerating CEO succession.

“Novo Nordisk’s strategy remains unchanged, and the Board is confident in the company’s current business plans and its ability to execute on the plans,” said Chairman Helge Lund.

Jørgensen’s tenure saw early success of Wegovy, Ozempic before Eli Lilly took over

Jørgensen has been with Novo Nordisk since 1991 and took over as CEO in 2017.

Under his leadership, the company cemented its lead in the growing global market for obesity and diabetes treatments, largely thanks to the success of Wegovy and Ozempic.

These drugs contributed to soaring sales and investor enthusiasm, turning Novo Nordisk into one of Europe’s most valuable companies.

However, recent developments have rattled investor confidence.

Eli Lilly’s obesity drug Zepbound has steadily gained traction in the United States, surpassing Wegovy in prescriptions since mid-March.

Meanwhile, results from Novo’s trials for next-generation obesity treatments have fallen short of expectations, casting doubts over the company’s future product pipeline.

Strategic partnerships to defend market share

In response to the competitive threat, Novo Nordisk has pursued several strategic partnerships.

Just a day before the CEO announcement, the company signed a collaboration agreement with biotech firm Septerna, potentially worth up to $2.2 billion.

The partnership aims to discover up to four new obesity therapies, with Septerna eligible for over $200 million in upfront and near-term payments.

Novo has also sought to expand access to its existing treatments through US telehealth firms like Hims & Hers, Ro, and LifeMD.

These partnerships allow for direct-to-patient distribution of Wegovy in the US, amid tighter regulations on compounding pharmacies that previously filled the gap during drug shortages.

Despite these efforts, the CEO transition marks a critical moment for Novo Nordisk as it navigates a more crowded and aggressive market landscape.

The post Novo Nordisk CEO to step down as obesity drug competition intensifies appeared first on Invezz

Previous Post

Why this investment bank sees more than 30% upside on Meta

Next Post

Rich List 2025: UK billionaires decline for first time in years amid market turmoil

admin

admin

Next Post
Rich List 2025: UK billionaires decline for first time in years amid market turmoil

Rich List 2025: UK billionaires decline for first time in years amid market turmoil

Trending News

From Ashtead to Flutter, what’s causing UK-listed companies to move listing to the US?

From Ashtead to Flutter, what’s causing UK-listed companies to move listing to the US?

December 10, 2024
CNH Industrial shares fall after third-quarter profit miss, forecast cut

CNH Industrial shares fall after third-quarter profit miss, forecast cut

November 8, 2024
Explained: why Dollar Tree investors should cheer the Family Dollar sale

Explained: why Dollar Tree investors should cheer the Family Dollar sale

March 26, 2025
Subscribe to Insightful Word


    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025
    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    August 7, 2025
    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    August 7, 2025

    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025

    Latest News

    • Dow futures soar 250 points today: 5 things to know before Wall Street opens
    • Affirm stock price is rising: is it a buy before earnings?
    • Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.